Vaijayantee Belle, MD
Neurology · Fort Myers, FLNPI 1063771178
Payments from drug & device makers
Across 222 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Biogen$592
- Pfizer$258
- Lilly USA, LLC$226
- Livanova USA, Inc.$184
- Biohaven Pharmaceutical Holding Company Ltd.$181
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,48799%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $1,145 |
| Biogen | 33 | $592 |
| Pfizer | 15 | $258 |
| Lilly USA, LLC | 13 | $226 |
| Livanova USA, Inc. | 5 | $184 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $181 |
| Medtronic(2 entities) | 2 | $177 |
| Johnson & Johnson | 4 | $166 |
| UCB, Inc. | 9 | $164 |
| Bristol Myers Squibb | 9 | $136 |
| Sunovion Pharmaceuticals Inc. | 7 | $133 |
| Neurelis, Inc. | 2 | $127 |
| Argenx US, Inc. | 5 | $123 |
| EMD Serono, Inc. | 5 | $110 |
| Mallinckrodt Hospital Products Inc. | 4 | $92 |
| Mallinckrodt Enterprises LLC | 4 | $85 |
| Impel Pharmaceuticals Inc. | 4 | $76 |
| Urovant Sciences Inc | 4 | $72 |
| Abbott | 1 | $64 |
| Acadia Pharmaceuticals Inc | 4 | $60 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| Amgen | 3 | $48 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Boston Scientific | 1 | $37 |
| Lundbeck LLC | 2 | $33 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| MDD US Operations, LLC | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| GE HealthCare | 1 | $14 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,546 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 35 | $311,241 |
| IngrezzaValbenazine Tosylate | 19 | $148,211 |
| RebifInterferon Beta-1a/Albumin | 11 | $112,044 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $105,733 |
| NuplazidPimavanserin Tartrate | 12 | $59,940 |
| BanzelRufinamide | 14 | $46,292 |
| Emgality PenGalcanezumab-Gnlm | 24 | $31,404 |
| QuliptaAtogepant | 23 | $25,991 |
| KeppraLevetiracetam | 14 | $18,431 |
| Nurtec OdtRimegepant Sulfate | 18 | $18,149 |
| Dalfampridine ErDalfampridine | 11 | $15,516 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $11,213 |
| Lacosamide | 40 | $9,902 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $7,330 |
| Levetiracetam | 215 | $5,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $32 | $148,21119 claims |
| EMD Serono, Inc.Rebif | $110 | $112,04411 claims |
| Acadia Pharmaceuticals IncNuplazid | $60 | $59,94012 claims |
| AbbVieQulipta | $1,145 | $25,99123 claims |
| PfizerNurtec Odt | $258 | $18,14918 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $53 | $2,02427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,434 neurology providers in Florida.
Other neurology in Fort Myers
- Wendy BondFort Myers$14.7M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.